GHK-Cu During Pregnancy and Lactation: What the Evidence Actually Shows

Is any GHK-Cu product approved?

No FDA-approved drug is known to contain GHK-Cu [1]. GHK-Cu is a different compound from copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [6].

Topical copper peptide serums are sold as cosmetics, and cosmetics do not need FDA approval before sale; a claim to treat disease or change the body's structure or function would make a product a drug [2]. Injectable GHK-Cu is not a cosmetic and is not FDA-approved [2]. Compounded drugs are not FDA-approved either, because FDA does not review their safety, effectiveness or quality before marketing [7].

What human data exist?

We found no study that measured GHK-Cu in breast milk or in infants. The two human randomized trials found were small and topical: one included 13 patients, the other 86 evaluable patients [4][5].

The first randomized skin care with or without GHK-Cu after CO2 laser resurfacing; computer analysis and blinded evaluators found no significant difference in redness, wrinkles or overall skin quality, while a patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [4]. The second found a 0.4% tripeptide copper complex cream no different from an inert vehicle placebo for ulcer size [5]. Neither abstract reports blood or milk copper, or pregnancy outcomes [4][5]. A 2026 systematic review kept 64 records and called the human literature thin and fragmented, with most randomized trials small and run on facial cosmetic creams [8].

What is known about copper in pregnancy?

Copper is an essential nutrient. A 2005 review notes that copper deficits during pregnancy can result in gross structural malformations in the conceptus and persistent neurological and immunological abnormalities in offspring, and that excessive copper can pose a risk too, with chronic toxicity causing liver disease and severe neurological defects [9].

Cupric chloride injection, an intravenous additive for total parenteral nutrition, is a different product from GHK-Cu. Its label says that animal reproduction studies have not been conducted with cupric chloride, that it is not known whether it can cause fetal harm in a pregnant woman, and that it should be given in pregnancy only if clearly indicated [10].

Does the route matter?

Yes, in regulation and in data. FDA lists 'GHK-Cu (for injectable routes of administration)' among substances nominated but later withdrawn, and states: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3]. Injectable GHK-Cu is not in any category on FDA's current list [1]. Non-injectable GHK-Cu sits in category 1, the group under evaluation for FDA's list of bulk substances that state-licensed pharmacies and physicians may use in compounding [1][11].